China’s drug regulator said on Saturday it had given “conditional” approval to the use of US-based Pfizer’s anti-Covid pill to treat adults with mild or moderate illness who may develop severe symptoms.
The National Medical Products Administration, which has so far not licensed any foreign COVID-19 vaccines, has also requested that more research on the drug be conducted and provided to it.
ehl/roc/dbh/dl